To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study. Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms. The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
A SCBM (DMTS) team, in collaboration with researchers at NeuroSpin and I2BC, is describing micellar nanometric vectors targeting tumors that have been imaged by fluorine magnetic resonance imaging (MRI). The observed 19F signal made it possible to precisely delimit the volume of the tumor zone in a mouse model and to quantify the probe accumulated in the target tissue.
The TIRO team (SHFJ), in collaboration with the neurovascular clinicians of the Nice and Marseille University Hospitals, carried out analyses of the metabolome of cerebral clots at the origin of the occlusion of a cerebral artery responsible for a cerebral vascular accident (stroke). A pilot study that improved the understanding of the complex relationship between blood glucose levels and patients' functional prognosis.
A study led by Oxford University researchers and involving researchers from the Institut Joliot (I2BC) and the University of Århus reveals the crucial role of the E340 residue in the inter-domain communication of the calcium transporter SERCA.
Coordinated by the Imagine Institute for Genetic Diseases, the ATRACTion program is based on a consortium of 11 academic and industrial partners, including SPI (DMTS), and aims to develop a precision medicine for patients with autoimmune and inflammatory diseases associated with primary immune deficiencies.
AROMA, a FET-Open H2020 project, aims to develop the methodology necessary for the optimal operation of the future 11.7 T MRI being installed at NeuroSpin. This 5-year project, coordinated by Nicolas Boulant (NeuroSpin), with an overall budget of 3.6 million euros, involving six partners from five countries representing academia and industry, started on January 1, 2021.
Researchers from I2BC and SPI (DMTS, Marcoule), in collaboration with CEA Grenoble and the Belgian nuclear research center, discovered, by using two meta-omic approaches, living bacteria in the core pool of the CEA Paris-Saclay research reactor, Osiris, in operation, thus opening up perspectives for the discovery of new radioresistant species.
A study led by the Institut Pasteur and involving CEA-Joliot has shown, in a mouse model, that a modification of the intestinal microbiota caused by chronic stress is accompanied by modifications of the metabolome which induce a defect in the signaling pathway for endogenous cannabinoids in the hippocampus, which may explain the mood disorders observed.
The European Commission once more places its trust on Multiwave company and its partners, Aix-Marseille Université , CEA and Université Catholique de Louvain to revolutionize ultra-high field magnetic resonance imaging of the brain.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.
